Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gatifloxacin

FDA-approved product (solution/drops, ophthalmic), marketed as Gatifloxacin, Zymar, Zymaxid.

Registered studies
39
Lab records
43
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Gatifloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Eye infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA16; WHO ATC S01AE06

Repurposing investigation

Gatifloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae90.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 5 of 5 lab records
  • K. pneumoniae: measured active in 14 of 14 lab records
  • M. tuberculosis: measured active in 21 of 21 lab records
Open Gatifloxacin in ChEMBL Registered studies below
Show the 43 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gatifloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intraocular Steroid After Cataract Surgery Study

    NCT00478764 · start 2006-03

    Registered record
    Registry ID
    NCT00478764
    Conditions
    Cataract
    Interventions
    intraocular triamcinolone and gatifloxicin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-04
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    Interventionintraocular triamcinolone and gatifloxicin
    PhaseNot applicable
    Registry statusCompleted

  • Proparacaine vs Placebo for Corneal Injuries

    NCT00620997 · start 2005-10

    Registered record
    Registry ID
    NCT00620997
    Conditions
    Corneal Abrasions
    Interventions
    Proparacaine drops 0.05%; saline drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Abrasions
    InterventionProparacaine drops 0.05%; saline drops
    PhasePhase 1
    Registry statusCompleted

  • A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis

    NCT00216385 · start 2005-01

    Registered record
    Registry ID
    NCT00216385
    Conditions
    Tuberculosis
    Interventions
    Gatifloxacin combined regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2005-01
    Completion
    2008-12
    Enrolment
    2,070

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionGatifloxacin combined regimen
    PhasePhase 3
    Registry statusUnknown

  • Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

    NCT00396084 · start 2004-02-10

    Registered record
    Registry ID
    NCT00396084
    Conditions
    Tuberculosis
    Interventions
    Gatifloxacin; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-02-10
    Completion
    2007-12-28
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionGatifloxacin; Isoniazid; Levofloxacin; Linezolid +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers

    NCT00651586 · start 2003-10

    Registered record
    Registry ID
    NCT00651586
    Conditions
    Acute Bacterial Corneal Ulcers; Bacterial Keratitis
    Interventions
    Gatifloxacin 0.3% ophthalmic solution; Ciprofloxacin 0.3% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-04
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Corneal Ulcers; Bacterial Keratitis
    InterventionGatifloxacin 0.3% ophthalmic solution; Ciprofloxacin 0.3% ophthalmic solution
    PhasePhase 2
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Therapeutic Variables in Cataract Surgery

    NCT00407017

    Registered record
    Registry ID
    NCT00407017
    Conditions
    Cataract Surgery
    Interventions
    Gatifloxacin; Ketorolac LS; Pred Forte; Moxifloxacin; Nepafenac; EconoPred Plus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Surgery
    InterventionGatifloxacin; Ketorolac LS; Pred Forte; Moxifloxacin +2 more
    PhasePhase 4
    Registry statusCompleted

  • Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

    NCT00414011

    Registered record
    Registry ID
    NCT00414011
    Conditions
    Epithelium, Corneal
    Interventions
    Moxifloxacin; Gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-02
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelium, Corneal
    InterventionMoxifloxacin; Gatifloxacin
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

    NCT00433225

    Registered record
    Registry ID
    NCT00433225
    Conditions
    Macula Thickening
    Interventions
    Prednisolone Acetate; Ketorolac 0.4%; Gatifloxacin 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacula Thickening
    InterventionPrednisolone Acetate; Ketorolac 0.4%; Gatifloxacin 0.3%
    PhasePhase 4
    Registry statusCompleted